DBRC
REGN icon

D.B. Root & Company’s Regeneron Pharmaceuticals REGN Stock Holding History

D.B. Root & Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-825
Closed -$339K – 206
2019
Q1 		$339K Sell
825
-60
-7% -$24.7K 0.14% 162
2018
Q4 		$331K Sell
885
-425
-32% -$156K 0.16% 142
2018
Q3 		$529K Sell
1,310
-900
-41% -$343K 0.23% 121
2018
Q2 		$762K Buy
2,210
+120
+6% +$37.5K 0.36% 96
2018
Q1 		$720K Buy
+2,090
New +$727K 0.38% 91

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

D.B. Root & Company's REGN Position: Q2 2019 in Review

D.B. Root & Company sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 825 shares — an estimated $339K sold.

D.B. Root & Company first reported a position in REGN in Q1 2018 and held it in 5 quarters. The position peaked at $762K in Q2 2018. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

  • D.B. Root & Company reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • D.B. Root & Company sold 825 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $339K.
  • D.B. Root & Company first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • D.B. Root & Company's Regeneron Pharmaceuticals position peaked at $762K in Q2 2018.
  • 658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on D.B. Root & Company's 13F filing for Q2 2019, filed 19 Jul 2019.